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Abstract
Background Several drugs may lower serum sodium con-
centrations (NaC) in older patients. However, distinguish-
ing their individual effects is particularly difficult in this
population because of the high prevalence of polyphar-
macy and disease states that are per se associated with
hyponatremia.
Objectives Our objective was to identify specific patterns
of medication use in older hospitalized patients and
determine whether these patterns were associated with
serum NaC.
Methods We collected clinical and demographic data, pre-
admission drugs, Drug Burden Index (DBI) score, and
average NaC during hospitalization in a consecutive series
of older medical patients (n = 101, mean ± standard
deviation [SD] age 87 ± 6 years). We used latent class
analysis (LCA) to identify specific patterns of drug use and
multivariate regression to determine the associations
between 14 separate drug classes, identified patterns of
drug use, and NaC.
Results LCA revealed three patterns: lower overall drug
use (class 1), anticoagulant use and higher drug use (class
2), and antiplatelet use (class 3). Mean (±SD) DBI score in
each class was 2.7 ± 1.3, 3.3 ± 1.6, and 2.4 ± 1.5,
respectively (p = 0.04). Mean (± SD) NaC in classes 1, 2,
and 3 were 140.6 ± 6.8, 138.7 ± 5.3, and
136.5 ± 4.7 mmol/l, respectively (p = 0.006). After
adjustment for age, sex, Charlson Comorbidity Index score,
estimated glomerular filtration rate (eGFR), DBI score, and
digoxin use, mean NaC in class 2 and class 3 was signifi-
cantly lower than in class 1 (-3.9 mmol/l; 95% confidence
interval [CI] -7.1 to -0.8, p = 0.01 and -5.2 mmol/l;
95% CI -7.9 to -2.5, p\ 0.001, respectively). Mean
serum NaC was not significantly associated with any of the
14 individually assessed drug classes. In addition to latent
class, increasing age and higher eGFR were also indepen-
dently associated with lower serum NaC (p = 0.002 and
p = 0.03, respectively).
Conclusion LCA enabled us to identify patterns of drug
use associated with lower serum NaC in older inpatients.
Our results suggest that older patients using antiplatelets or
anticoagulants are especially at risk of lower serum NaC.
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Key Points
Distinguishing the individual effects of drugs on
serum sodium (Na) concentrations in older inpatients
is difficult because of the high prevalence of
polypharmacy and disease states that are per se
associated with hyponatremia.
To investigate associations between drug use,
clinical characteristics, and serum Na concentrations
in older inpatients, we applied a clustering technique
known as latent class analysis (LCA) to identify
specific patterns of drug use.
By identifying patterns of drug use with LCA, we
established that age, eGFR, antiplatelet drugs, and
anticoagulants are independently associated with
lower serum Na concentrations.
1 Introduction
Serum sodium concentrations (NaC)\135 mmol/l (hy-
ponatremia) are observed in up to 50% of older patients
admitted to hospital [1, 2]. The high prevalence of this
electrolyte abnormality in older hospitalized patients might
be secondary to the presence of one, or more, disease states
characterized by alterations in sodium and water balance,
impaired homeostasis, and polypharmacy, as well as in-
hospital iatrogenic interventions [3]. There is increasing
evidence that lower NaC values are independently associ-
ated with adverse clinical outcomes in old age [3]. More
specifically, they predict loss of independence, increased
length of stay, and mortality in older hospitalized patients
[4–6].
Several drugs and drug classes, e.g., diuretics, antide-
pressants, and antiepileptics, are known to reduce NaC.
Proposed mechanisms for these reductions include alter-
ations in sodium and water homeostasis, potentiation of the
physiological effects of the antidiuretic hormone, and
resetting of control mechanisms located in the hypothala-
mus [7]. However, it is possible that associations between
NaC and the use of diuretics, antidepressants, antiepilep-
tics, and other drug classes are at least partly explained by
the disease state for which these drugs are prescribed in the
first instance [8].
The increased risk of hyponatremia, an independent
predictor of adverse outcomes in the older population, with
several commonly prescribed drugs warrants regular
medication reviews to prevent and rectify this electrolyte
abnormality, potentially improving outcomes in this group
[3]. However, investigating associations between drugs and
NaC in patients with concomitant prescribed medications
and multiple disease states presents significant challenges.
In particular, it is extremely difficult to disentangle the
independent effects on NaC of individual drugs and other
clinical and demographic parameters [7]. One method-
ological approach that might be useful in simplifying the
problem of trying to identify likely associations between
drugs and NaC is to group individuals by their most dis-
tinctive patterns of medication use, typically using two to
four groups to make interpretation easier. If examination of
the resulting classes reveals a very high probability of
either using or avoiding a particular medication, this raises
the possibility that any observed differences in clinical
characteristics (such as NaC) between the classes may
partly be due to use of that medication. Such an approach
also helps increase the external validity and clinical rele-
vance of the study since, in the real world, older patients
generally take a multitude of medications, which is cap-
tured in the resulting groups.
To investigate the independent associations between
drug use and NaC in older hospitalized patients, we applied
a clustering technique known as latent class analysis (LCA)
to identify specific patterns of drug use. We then deter-
mined whether these patterns were associated with lower
NaC.
2 Methods
2.1 Study Population
We retrospectively studied a consecutive series of 101
patients aged C75 years who were admitted to general
medicine wards at Flinders Medical Centre, a 450-bed
metropolitan teaching hospital in the Southern Adelaide
Local Health Network, Adelaide, Australia, between 30
October 2014 and 1 May 2015 and subsequently dis-
charged to a residential aged care facility. The study was
approved by the Southern Adelaide Clinical Human
Research Ethics Committee (Ethics Approval Number:
457.14).
2.2 Clinical and Demographic Variables
Data on age, sex, and comorbidities were collected from
individual patient’s clinical notes, discharge summaries,
and pathology results. This information was used to
calculate the Charlson Comorbidity Index (CCI) score
for each patient. The CCI, widely used in clinical
research as a measure of comorbidity and a prognostic
indicator for survival, encompasses 19 medical
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conditions weighted with a score of 1 to 6, with total
scores ranging from 0 to 37 [9].
2.3 Medication Exposure
Medication exposure at the time of hospital presentation
was characterized as type of medication, total number of
medications, and Drug Burden Index (DBI) score. A
comprehensive list of all medications on admission was
formulated by a pharmacist. This involved a minimum of
three sources of information (e.g., patient interview, carer/
relative interview, phone call to community pharmacy,
general practitioner medication list, patient’s own medi-
cations, phone call to aged care facility manager). The DBI
score was also assessed as an established measure of
exposure to drugs with sedative and/or anticholinergic
effects, which includes several drugs associated with an
increased risk of hyponatremia [7, 10, 11]. The drug burden
(DB) was calculated for each patient according to the fol-
lowing equation:
DB ¼ BAC þ BS
where BAC and BS indicate the burden from anticholinergic
and sedative drugs, respectively. The DBI for each
anticholinergic or sedative drug was calculated using the
following equation, as previously described [10]:
DBI ¼
X
½D=ðdþ DÞ
where D is the daily dose and d is the minimum recom-
mended daily dose approved by the Australasian Society of
Clinical and Experimental Pharmacologists and Physiolo-
gists, the Royal Australasian College of General Practi-
tioners, and the Pharmaceutical Society of Australia
(Australian Medicines Handbook). The minimum recom-
mended daily dose was used as an estimate of the dose
required to achieve 50% of the maximum anticholinergic
or sedative effect. Complementary medications, topical
medications, or medications instructed to be taken as
required were excluded from the DBI calculations.
2.4 Biochemical Parameters
Data on NaC and estimated glomerular filtration rate
(eGFR) were captured from the hospital electronic data-
base (OACIS Clinical Care Suite Safety Learning System,
Government of South Australia). Patients were regularly
assessed for NaC and eGFR throughout their hospital stay
as part of their routine clinical assessment. The number of
individual tests varied according to the reason for admis-
sion and length of hospital stay. For analysis purposes, we
used the mean NaC and eGFR across all of their
assessments.
2.5 Statistical Analysis
We performed an LCA based on the use or not of 14
separate commonly used drug classes (listed in Table 1).
The LCA thus grouped patients according to their most
specific patterns of drug use, and their class membership
was decided by their highest (posterior) predicted proba-
bility of class membership. We used the Akaike Infor-
mation Criterion (AIC) statistic to assess the model fit for
three different models, specifying two, three, or four latent
classes. Following the LCA, the distinctive characteristics
of each class was determined based on the observed drug
use distributions, and an appropriate label was then
assigned to each class. We then performed several dif-
ferent analyses based on the newly formed latent classes.
First, we compared differences across the latent class
groups in patient characteristics and individual drug use in
univariate analysis, using one-way analysis of variation
(ANOVA) for continuous variables and Fisher’s exact test
for categorical variables. Then, to establish whether dif-
ferences in NaC based on medication use could also be
revealed using a more standard regression approach, we
used multivariate linear regression to compare mean NaC
for users/non-users of each medication class after adjust-
ment for age, sex, CCI score, DBI score, and eGFR, which
were each considered to be potential confounders in the
relationship between NaC and medication use. The esti-
mated marginal mean differences between users/non-users
were calculated and assessed for significance. We also
performed an additional multivariate analysis for mean
NaC and each medication excluding the DBI score from
the adjustment. Results were substantively the same and
are not reported. A similar analysis was performed to
compare differences in mean NaC between latent classes,
with models that were unadjusted (model 1), and adjusted
for age, sex, CCI and DBI scores, and eGFR (model 2). In
a final model (model 3), we also adjusted for digoxin use,
since patients with heart failure are known to have lower
NaC. Lower eGFR and digoxin use are indicators of renal
and heart failure, respectively, which may also affect NaC
and confound potential medication use/NaC associations.
Finally, we performed multinomial logistic regression
with latent class membership as the nominal categorical
dependent variable and NaC for each individual as the
exposure variable of interest. This is a standard approach
following LCA; it enables calculation of the estimated
probabilities of class membership for any given NaC and
plotting of the marginal posterior probabilities against
each other. The analysis of NaC was based on mean
values for each individual across their hospital stay, which
ranged from one to ten tests. Similarly, the analysis of
eGFR was also based on the mean eGFR values during
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hospital stay, which ranged from one to ten except for
eight individuals who were not assessed. The LCA was
performed using the poLCA package in R software, which
performs LCA for polytomous outcome variables. All
other analysis was performed using STATA (StataCorp,
version 14.1, College Station, TX, USA). A type 1 error
rate of a = 0.05 was considered statistically significant
for all analyses.
3 Results
Medication use for each of the 14 listed drug classes
(Tables 1, 2) was completed for all subjects, and the LCA
was therefore based on all 101 subjects. Mean eGFR data
were missing for seven subjects who were therefore not
included in the multivariate regression models, which were
analysed using 94 subjects (Table 3).
Table 1 Clinical characteristics according to latent medication use class membership
Characteristic Class 1: lower medication use
(N = 27)
Class 2: anticoagulant users
(N = 28)
Class 3: antiplatelet users
(N = 46)
p valuea
Males 11 (40.7) 10 (35.7) 19 (41.3) 0.90
Admitted from 0.81
Home 12 (44.4) 14 (50.0) 24 (52.2)
Aged care facility 15 (55.6) 14 (50.0) 22 (47.8)
Age, years 89 ± 7 86 ± 6 87 ± 5 0.18
CCI score 2.9 ± 2.1 3.9 ± 2.1 2.8 ± 1.7 0.04
eGFR (ml/min) 49 ± 23 44 ± 24 53 ± 21 0.85
NaC (mmol/l) 140.6 ± 6.8 138.7 ± 5.3 136.5 ± 4.7 0.006
NaC\135 mmol/lb 7 (25.9) 8 (28.6) 23 (50.0) 0.07
NaC\135 mmol/lc 8 (30) 9 (32) 23 (50) 0.16
DBI 2.70 ± 1.35 3.32 ± 1.59 2.41 ± 1.48 0.04
Medications used 2 (0–5) 5 (4–9) 4 (2–8) \0.001
Number of NaC tests 4.6 ± 3.0 5.0 ± 2.9 5.2 ± 3.0 0.70
Number of eGFR tests 3.7 ± 3.0 4.6 ± 3.2 5.0 ± 3.0 0.25
Individual medication use
Antiplatelets 3 (11.1) 2 (7.1) 45 (97.8) \0.001
Anticoagulants 0 (0.0) 28 (100.0) 1 (2.2) \0.001
Statins 2 (7.4) 16 (57.1) 18 (39.1) \0.001
Proton pump
inhibitors
11 (40.7) 18 (64.3) 22 (47.8) 0.20
Digoxin 1 (3.7) 6 (21.4) 8 (17.4) 0.13
Oral hypoglycemics 0 (0.0) 7 (25.0) 6 (13.0) 0.01
Bisphosphonates 0 (0.0) 3 (10.7) 7 (15.2) 0.11
Benzodiazepines 2 (7.4) 7 (25.0) 4 (8.7) 0.10
Diuretics 7 (25.9) 20 (71.4) 21 (45.6) 0.003
ACEI/ARB 7 (25.9) 7 (25.0) 16 (34.8) 0.64
Beta-blockers 6 (22.2) 21 (75.0) 17 (37.0) \0.001
Antipsychotics 0 (0.0) 0 (0.0) 6 (13.1) 0.03
Opioids 6 (22.2) 6 (21.4) 7 (15.2) 0.68
Antidepressants 15 (55.6) 20 (71.4 23 (50.0) 0.19
Data are presented as mean ± standard deviation, n (%), or median (range)
ACEI angiotensin-converting enzyme inhibitor, ANOVA analysis of variance, ARB angiotensin receptor blocker, CCI Charlson Comorbidity
Index, DBI Drug Burden Index, eGFR estimated glomerular filtration rate, NaC serum sodium concentration
a Using Fishers exact test for categorical variables and one-way ANOVA for continuous variables
b NaC on admission to hospital
c Period prevalence from NaC values during hospital stay
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3.1 Latent Class Analysis
The AIC statistic for the LCA models with two, three,
and four classes was 1499.6, 1500.9, and 1505.4,
respectively. Although the optimal number of classes
was therefore two based on using the smallest AIC for
best model fit, we chose to use three classes since each
of the three classes had a distinctive medication class
use pattern. These patterns were characterized as fol-
lows: lower medication use (class 1), anticoagulant users
combined with higher overall medication use (class 2),
and antiplatelet users (class 3).
Table 2 Observed mean
sodium concentrations by non-
use/use of individual
medications (n = 101)
Medication (no. of users) Non-users Users Users vs. non-users (p value)a
Antiplatelets (n = 50) 139.3 ± 6.0 137.2 ± 5.2 -1.9 ± 1.2 (0.11)
Anticoagulants (n = 29) 138.1 ± 5.9 138.6 ± 5.2 -0.9 ± 1.4 (0.50)
Statins (n = 36) 137.8 ± 6.2 139.0 ± 4.6 -0.6 ± 1.3 (0.68)
PPI (n = 51) 138.9 ± 5.9 137.6 ± 5.5 -1.9 ± 1.2 (0.12)
Digoxin (n = 15) 138.1 ± 5.9 139.0 ± 4.2 1.3 ± 1.7 (0.44)
Oral hypoglycemics (n = 13) 138.3 ± 5.8 138.0 ± 4.7 -2.5 ± 1.8 (0.16)
Bisphosphonates (n = 10) 138.2 ± 5.8 138.8 ± 4.7 -0.6 ± 2.1 (0.75)
Benzodiazepines (n = 13) 138.3 ± 5.9 138.1 ± 3.5 -0.5 ± 2.0 (0.79)
Diuretics (n = 48) 138.5 ± 6.2 138.0 ± 5.0 -1.1 ± 1.2 (0.38)
ACEI/ARB (n = 30) 138.7 ± 6.1 137.2 ± 4.4 -1.3 ± 1.3 (0.31)
Beta-blockers (n = 44) 138.4 ± 5.9 138.0 ± 5.4 -1.5 ± 1.2 (0.23)
Antipsychotics (n = 6) 138.5 ± 5.7 134.7 ± 4.6 -3.3 ± 2.4 (0.16)
Opioids (n = 19) 137.8 ± 5.6 140.3 ± 5.8 2.5 ± 1.7 (0.15)
Antidepressants (n = 58) 138.7 ± 4.9 137.9 ± 6.2 -0.9 ± 1.2 (0.46)
Data are presented as observed mean ± standard deviation
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, PPI proton pump
inhibitor
a Marginal mean difference and associated p value for users vs. non-users using multivariate linear
regression adjusted for age, sex, Charlson Comorbidity Index score, Drug Burden Index, and estimated
glomerular filtration rate
Table 3 Results from simple (n = 101) and multivariate (n = 94) linear regression showing estimated differences in mean serum sodium
concentrations (mmol/l) by latent pattern of medication use
Model 1 p value Model 2 p value Model 3 p value
Latent class
Class 1 (lower medications) Reference – Reference – Reference –
Class 2 (anticoagulants) -2.0 (-4.9 to 1.0) 0.18 -3.5 (-6.6 to -0.4) 0.03 -3.9 (-7.1 to -0.8) 0.01
Class 3 (antiplatelets) -4.3 (-6.9 to -1.6) 0.002 -4.7 (-7.4 to -2.1) 0.001 -5.2 (-7.9 to -2.5) <0.001
Age, years -0.34 (-0.56 to -0.13) 0.002 -0.34 (-0.55 to -0.13) 0.002
Charlson comorbidity score -0.16 (-0.75 to 0.43) 0.60 -0.17 (-0.76 to 0.42) 0.56
Male vs. female -0.8 (-3.1 to 1.6) 0.51 -0.6 (-3.0 to 1.7) 0.58
eGFR category (ml/min)
0–29 Reference – Reference –
30–59 -3.1 (-6.3 to 0.0) 0.05 -3.2 (-6.3 to -0.0) 0.048
60–90 -4.3 (-7.6 to -1.0) 0.01 -4.3 (-7.6 to -1.1) 0.01
Drug burden index 0.16 (-0.61 to 0.93) 0.69 0.1 (-0.6 to 0.9) 0.75
Digoxin use (yes vs. no) 2.5 (-0.7 to 5.7) 0.13
Data are presented as b (95% confidence interval) unless otherwise indicated. Model 1: unadjusted analysis. Model 2: model 1 plus adjustment
for age, sex, Charlson Comorbidity Index score, Drug Burden Index, and eGFR. Model 3: model 2 plus adjustment for digoxin use
Significant p values are in bold
eGFR estimated glomerular filtration rate
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3.2 Clinical Characteristics
Table 1 displays the clinical characteristics of the patients
according to their latent class membership. There were no
differences between groups in sex, age, and eGFR. The
CCI score was highest amongst subjects in class 2. This
class also had a significantly higher DBI score than the
other two classes (p = 0.04). The median number of
medications used in classes 1, 2, and 3 was two, five, and
four, respectively (p\ 0.001). The use of statins, beta-
blockers, and diuretics were all significantly higher in class
2 than in the other two classes.
3.3 Serum Sodium (Na) Concentration: Univariate
Analysis
The mean (±standard deviation [SD]) number of NaC
assessments during hospital stay for the 101 subjects with
at least one test was 5 ± 3 (range 1–10). In univariate
analysis, there was no difference in the number of assess-
ments performed across the three latent classes. However,
mean NaC decreased significantly across classes
(p = 0.006) (Table 1): it was significantly lower for class 3
than for class 1 (p = 0.002) but not class 2 (p = 0.18).
3.4 Serum Na Concentration: Multivariate Analysis
Table 2 shows the observed mean (±SD) NaC for non-
users and users of each of the 14 medication classes. After
adjustment for age, sex, CCI and DBI score, and eGFR, the
adjusted marginal mean differences were not significantly
different between classes for any of the separate medica-
tion classes. Table 3 shows the estimated coefficients from
the multivariate linear regression, which included latent
class membership rather than individual drug classes. After
adjustment for age, sex, CCI and DBI score, and eGFR
(model 2), the mean NaC among patients in class 2 and
class 3 were significantly lower than among those in class 1
(-3.5 mmol/l; 95% confidence interval [CI] -6.6 to -0.4,
p = 0.03 and -4.7 mmol/l; 95% CI -7.4 to -2.1,
p = 0.001, respectively). The additional adjustment for
digoxin use in model 3 increased the differences for class 2
and class 3 versus class 1 (-3.9 mmol/l; 95% CI -7.0 to -
0.8, p = 0.02 and -5.2 mmol/l; 95% CI -7.9 to -2.5,
p\ 0.001, respectively). Increasing age and higher eGFR
were also independently associated with lower NaC
(p = 0.002 and p = 0.03, respectively). We also per-
formed sensitivity analyses in which we used NaC on
admission as the outcome rather than the mean values for
each individual across their hospital stay. The pattern of
results was similar, and the differences for class 2 and class
3 versus class 1 was slightly larger (-5.5 mmol/l; 95% CI
-9.7 to -1.2, p = 0.01 and -6.9 mmol/l; 95% CI -10.6
to -3.3, p\ 0.001, respectively). Figure 1 shows the
adjusted marginal mean NaC and 95% CIs according to age
and class membership.
3.5 Class Membership Probabilities
In multinomial logistic regression after adjustment for the
predictors in model 3 above, patients with lower NaC were
significantly less likely to be within class 1 (low medica-
tion use) than within class 2 (anticoagulant users, odds ratio
[OR] 0.87, 95% CI 0.76–0.99, p = 0.03) or class 3 (an-
tiplatelet users, OR 0.82, 95% CI 0.72–0.92, p = 0.001).
Fig. 1 Marginal mean serum sodium concentration (mmol/l) by age
and latent class of medication use. Mean was calculated using
multivariate linear regression and adjusted for age, sex, Charlson
Comorbidity Index score, Drug Burden Index, estimated glomerular
filtration rate, and digoxin use
Fig. 2 Probability of latent class membership by mean serum sodium
concentration during hospital admission. Probabilities are for mem-
bership in each particular class for a given serum sodium concen-
tration; the sum of the three probabilities at each serum sodium
concentration sum to 1. The multinomial logistic regression model
was adjusted for age, sex, Charlson Comorbidity Index, estimated
glomerular filtration rate, and Drug Burden Index. Vertical bars
represent 95% confidence intervals
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Figure 2 shows the predicted probabilities of class mem-
bership for each given NaC. This shows, for example, that
a patient with an NaC of approximately 120 mmol/l and
other covariates held constant has an approximately 80%
probability of being an antiplatelet user.
4 Discussion
We used LCA to characterize patterns of drug use in a
consecutive series of older patients admitted to general
medicine wards and subsequently discharged to an aged
care facility. We observed significant differences in NaC
according to the pattern of medication use. Patterns that
reflected a high probability of antiplatelet or anticoagulant
medication use had lower NaC values than patterns of
lower overall medication anticoagulant use. Although
patients who used anticoagulants generally had a slightly
higher overall pattern of use and reduced likelihood of
antiplatelet or medication use, our findings remained con-
sistent after adjusting for DBI and CCI score, age, eGFR,
and digoxin use. In addition, age, CCI score, and eGFR
were also independently associated with NaC, which
strengthens the validity of the study given that these factors
are all known confounders. The similar results obtained
when assessing NaC on admission rather than the mean
concentrations during hospitalization further supports the
presence of independent associations between lower NaC
and antiplatelet drugs and anticoagulants. Our approach
enabled us to take account for the general background of
multiple medication use and comorbidities that typically
exists among older patients. It also revealed significant
associations that could not be identified when these medi-
cations were assessed for association in isolation.
A number of reviews have elegantly discussed the
available evidence of the causative role of several drugs on
the risk of hyponatremia, particularly in older patients
[3, 7, 12]. However, a substantial number of studies (1)
comprised small population groups and case reports, (2)
included patients only receiving the investigated drug, and
(3) did not ascertain the potential contributing role of other
clinical and demographic characteristics on the incidence
of hyponatremia [3, 7, 12]. These issues are particularly
relevant in older patients with multiple disease states and
polypharmacy.
We observed significant independent associations
between lower NaC and the patterns of drug use character-
ized by the concomitant use of antiplatelet and anticoagulant
drugs. By contrast, no associations were observedwith drugs
previously reported as causing hyponatremia, such as proton
pump inhibitors, oral hypoglycemics, diuretics, inhibitors of
the renin-angiotensin system, antipsychotics, and antide-
pressants [13–18]. To the best of our knowledge, this is the
first report to describe an independent association between
patterns of drug use dominated by the use of antiplatelet
drugs and anticoagulants and lower NaC. Both classes of
drugs are routinely prescribed in primary and secondary
cardiovascular prevention as well as in other pro-thrombotic
states. The high prevalence of disease states associated per se
with lower NaC in patients prescribed either antiplatelet
drugs or anticoagulants, e.g., heart failure, renal failure, and
fluid overload, might potentially explain our findings. In
other words, the association between NaC and antiplatelet
drugs and anticoagulants might represent confounding by
indication. However, this hypothesis is not supported by the
lack of associations observed in our study between lower
NaC and other drugs often co-prescribed with antiplatelet
drugs and/or anticoagulants, e.g., statins, oral hypo-
glycemics, diuretics, inhibitors of the renin-angiotensin
system, and beta-blockers. Confirmation is required in larger
studies in different populations, and further research is also
required to identify the mechanisms responsible for a pos-
sible effect of antiplatelet drugs and anticoagulants on
sodium homeostasis.
Increasing age and higher eGFR were also associated
with lower NaC. A negative association between age and
NaC has been previously reported in older patients pre-
senting to hospital. In multivariate regression analysis,
Lindner et al. [19] observed that both age[60 years (OR
2.5, 95% CI 1.9–3.0, p\ 0.001) and use of diuretics (OR
1.9, 95% CI 1.7–2.2, p\ 0.001) were independently
associated with hyponatremia in 20,667 patients attending
the emergency department. In this study, the strong nega-
tive association between age and NaC was also observed in
patients not treated with diuretics [19]. It is therefore
possible that ageing per se causes alterations of sodium and
water homeostasis either peripherally, e.g., kidney, or
centrally, e.g., osmotic receptors in the hypothalamus [20].
Chronic kidney disease, hence a reduced eGFR, is associ-
ated with an increased incidence of either hypo- or
hypernatremia [21]. A large population study by Kovesdy
et al. [22] investigated the prevalence of hyponatremia and
hypernatremia in 655,493 US veterans according to the
different stages of chronic kidney disease. Overall, the
prevalence of hyponatremia was higher than that of
hypernatremia (13.5 vs. 2.0%). Interestingly, the relative
prevalence of hyponatremia was higher in the early stages
of chronic kidney disease, whereas the prevalence of
hypernatremia was higher in the more advanced stages
[22]. Unlike our study, Kovesdy et al. [22] included both
inpatient and outpatient populations. Moreover, no multi-
variate analysis was performed to assess independent
associations between eGFR and NaC. Further studies in
larger patient populations are required to confirm the
presence of an independent association between higher
eGFR and hyponatremia in older hospitalized patients.
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Our conclusions rely partly on being able to accurately
characterize the three latent classes that were first deter-
mined based on statistical analysis alone. Although there
was some overlap in medication use across classes, almost
all subjects in class 2 used anticoagulants, almost all sub-
jects in class 3 used antiplatelets, no subjects in class 1
used anticoagulants, and only three in class 1 used anti-
platelets. Therefore, identifying the main distinguishing
feature of each class was straightforward, increasing the
likelihood that the observed differences in NaC between
classes may have been due to differences in the use of these
two medications.
The study has a number of limitations. Only a fairly
limited number of clinical variables were assessed.
Therefore, the possibility of unobserved residual con-
founding remains. In addition, we did not have information
on the primary diagnosis at presentation. Although the
latter might have affected NaC per se during hospitaliza-
tion, this would only cause biased estimates for the asso-
ciations if there was an imbalance in conditions associated
with lower NaC across the three classes. In addition,
although all subjects in class 2 used anticoagulants, they
also had a slightly higher medication use overall. However,
adjusting for either the number of medications used or the
DBI score did not alter our findings. Our sample size was
fairly small, and information on eGFR was missing for
some subjects. This means that a larger sample size may
have enabled us to observe a significant difference in NaC
between individuals in classes 2 and 3. However, the mean
marginal difference of approximately 1.1 mmol/l is unli-
kely to be clinically significant. We have no data on how
and when medications were changed after admission or
how prescribing changes affected NaC and vice versa.
Similarly, we were unable to discriminate between short-
term and chronic use medications upon admission. How-
ever, our sensitivity analyses on NaC on admission confirm
the presence of independent associations between lower
NaC and antiplatelet drugs and anticoagulants. A further
limitation was that we conducted our study in a single
hospital using admissions between November and April,
inclusively. Therefore, our results need to be replicated in
larger multicentre studies, using admissions from a non-
summer period, before they can be made more generaliz-
able. Finally, since our study was cross-sectional in nature,
we cannot be sure of whether or not the observed associ-
ations were causal. However, it is unlikely that low NaC or
a disease state associated with hyponatremia would be an
indicator for the use of antiplatelet drugs or anticoagulants.
The study also has a number of strengths. Attempting to
assess the impact of individual medications on NaC is often
problematic because of the observational nature of studies
as well as the presence of polypharmacy and multiple
disease states in older patients. Using LCA allows a
‘subject-focused’ as opposed to a ‘variable-based’
approach, which tries to assess the impact of individual
variables. We were also able to use multiple measures of
NaC for each individual patient, thereby increasing the
accuracy of the true underlying NaC for each individual.
Finally, we were able to adjust for several important clin-
ical and demographic variables that may influence the
association between medication use and NaC, including
age and eGFR, which were also associated with NaC.
5 Conclusion
Our results are the first to show a substantially higher
likelihood of lower NaC among patients using either anti-
platelet drugs or anticoagulants combined with higher
medication use in general. Further studies are needed to
replicate our findings and to determine the impact of these
medications when taken in isolation and when used by a
younger population over time.
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